Abstract A35: Precision targeting of Homologous Recombination-deficient cancers using microRNA synthetic lethality
Conclusions: Packaging miR223-3p in a nanoparticle can be a potential therapeutic for HR-deficient malignancies and it can confer less risk of toxicity to normal cells since this microRNA is naturally present in mammalian cells.Citation Format: Gayathri Srinivasan, Elizabeth Williamson, Robert Hromas. Precision targeting of Homologous Recombination-deficient cancers using microRNA synthetic lethality [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr A35.
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Srinivasan, G., Williamson, E., Hromas, R. Tags: Finding Synthetic Lethal Interactions through Functional Genomics: Poster Presentations - Proffered Abstracts Source Type: research
More News: Addiction | Asbestosis | Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Mesothelioma | Nanotechnology | Ovarian Cancer | Ovaries | Study | Toxicology